Medicine & Life Sciences
Structure-Activity Relationship
100%
Protein-Arginine N-Methyltransferases
67%
Lysine
65%
Proteolysis
58%
Epigenomics
57%
Methyltransferases
56%
Histone-Lysine N-Methyltransferase
50%
Histones
45%
Polycomb Repressive Complex 2
44%
Methylation
43%
Neoplasms
43%
Ligands
41%
Proteins
40%
Chromatin
37%
Enhancer of Zeste Homolog 2 Protein
36%
Multiple Myeloma
31%
urotensin II
31%
UNC1999
28%
Protein Methyltransferases
28%
Ubiquitin-Protein Ligases
27%
Arrestin
26%
Muscarinic Receptors
23%
Therapeutics
21%
G-Protein-Coupled Receptors
20%
In Vitro Techniques
20%
Genes
19%
Dopamine Agonists
18%
Cholinergic Antagonists
18%
Nicotinamide N-Methyltransferase
17%
Acute Myeloid Leukemia
17%
clozapine N-oxide
16%
Pyridones
16%
Dopamine D2 Receptors
16%
Pharmacology
16%
Histone Methyltransferases
16%
Proteasome Endopeptidase Complex
15%
Leukemia
15%
Carcinogenesis
15%
Designer Drugs
15%
Quinazolines
15%
UNC 0638
14%
Pharmacokinetics
14%
Pharmaceutical Preparations
14%
Phosphotransferases
14%
Histone Code
14%
Triple Negative Breast Neoplasms
13%
Arginine
13%
Growth
13%
Binding Sites
12%
human GPBAR1 protein
12%
Chemical Compounds
Protein
74%
Histone
69%
Structure-Activity Relationship
67%
Lysine
60%
Agent Interacting With Transmitter, Hormone or Drug Receptor
50%
Protein Hydrolysis
41%
Arginine
38%
High Throughput Screening
33%
Antagonist
33%
Urotensin Receptor Antagonist
32%
Agonist
30%
H3K27Me3
29%
Parasympathomimetic Agent
25%
Ligand
23%
Oncogenic
21%
Acetylcholine
18%
Tyrosine
16%
Molecule
15%
Probe
15%
Partial Agonist
14%
Heterodimerization
14%
Drug
14%
Pharmacokinetics
14%
Vinylarene
14%
Dopamine
13%
Dopamine 1 Receptor Stimulating Agent
12%
Methyltransferase Inhibitor
12%
Mutation
11%
Hydrovinylation
11%
Antiparkinson Agent
10%
Nicotinamide
10%
Peptide
10%
Disorder
9%
Modification
8%
Intranasal
7%
Sulfonamide
7%
Enhancer
7%
Amide
7%
Biaryl
7%
Cofactor
7%
Phosphotransferase Inhibitor
7%
Stereochemistry
7%
Aripiprazole
7%
Intraperitoneal
7%
Cariprazine
7%
Intracolonic
7%
JQ1
6%
Binding Site
6%
Crystal Structure
6%
Application
6%